12 completed. 4 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Chronic Myeloid Leukaemia: new trials by email Literature Review of Chronic Myeloid Leukaemia trials Research Report on Chronic Myeloid Leukaemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry - Chronic Myeloid Leukaemia | Completed | Samara State Medical University | 105 | 2022-10-01 | 2026-10-16 | |
| Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia Chronic Myeloid Leukaemia | Completed | Novartis Pharmaceuticals | 555 | 2021-04-27 | 2023-06-08 | |
| Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database Bosutinib, Imatinib, Nilotinib - Chronic Myeloid Leukaemia | Completed | Pfizer | 1484 | 2020-11-18 | 2023-10-27 | |
| A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands Bosutinib - Chronic Myeloid Leukaemia | Completed | Pfizer | 87 | 2015-07-15 | 2023-10-03 | |
| Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia Nilotinib, Pegylated interferon alpha-2b, Imatinib - Chronic Myeloid Leukaemia | Phase 2 | Completed | Australasian Leukaemia and Lymphoma Group | 60 | 2014-04-11 | 2024-08-06 |
| De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia Imatinib, nilotinib, dasatinib - Chronic Myeloid Leukaemia | Phase 2 | Completed | University of Liverpool | 174 | 2013-12-01 | 2025-03-14 |
| Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase Chronic Phase Philadelphia Positive, BCR-ABL Positive | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 129 | 2013-06-21 | 2025-04-18 | |
| Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers Reduced intensity haplodentical stem cell transplant, Myeloablative haploidentical stem cell transplant - Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | Phase 2 | Completed | University College, London | 77 | 2013-03-01 | 2024-05-03 |
| Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib Imatinib - Chronic Myeloid Leukaemia | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 19 | 2012-09-13 | 2022-10-25 | |
| WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study WT1 TCR-transduced T cells - Acute Myeloid Leukaemia, Chronic Myeloid Leukaemia | Phase 1 / Phase 2 | Completed | Cell Medica Ltd | 7 | 2012-04-01 | 2018-10-02 |
| Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib Imatinib stop - Chronic Myeloid Leukaemia | Not applicable | Completed | University Hospital, Bordeaux | 220 | 2011-04-06 | 2026-07-31 |
| Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Glivec, Interferon - Chronic Myeloid Leukaemia | Phase 4 | Completed | PETHEMA Foundation | 360 | 2003-07-01 | 2008-11-27 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (12) · Leukemia, Myeloid, Acute (2) · Bronchiolitis Obliterans Syndrome (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Bone Marrow Diseases (12) · Chronic Disease (12) · Disease Attributes (12) · Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Leukemia, Myeloid (12) · Myeloproliferative Disorders (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12) · Leukemia (11) · Immune System Diseases (2) · Bronchial Diseases (1) · Bronchiolitis (1)
Imatinib Mesylate (5) · nilotinib (3) · Dasatinib (2) · bosutinib (2) · Interferons (1) · peginterferon alfa-2b (1) · ponatinib (1)
Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · Pfizer (2) · Australasian Leukaemia and Lymphoma Group (1) · Cell Medica Ltd (1) · Novartis Pharmaceuticals (1) · PETHEMA Foundation (1) · Samara State Medical University (1) · University College, London (1) · University Hospital, Bordeaux (1) · University of Liverpool (1)
United Kingdom (5) · Italy (2) · Australia (1) · France (1) · Hungary (1) · Russia (1) · Spain (1)
Andrew Grigg, MBBS, MD, FRACP, FRCPA (1) · Cervantes Francisco, Dr (1) · David Yeung, BSc(Med), MBBS(Hons),FRACP (1) · Dr Kavita Raj (1) · Emma Morris, Dr (1) · Gianantonio Rosti, Pr. (1) · Richard E Clark, MA MD (1) · Sabina Cherenova (1) · Tim Hughes, MBBS, MD, FRACP, FRCPA (1)